Recombinant Human CCL26 Protein，His

CCL26, also known as eotaxin-3, is a chemokine primarily involved in the recruitment of eosinophils and other immune cells to sites of inflammation, playing a critical role in allergic responses and asthma pathogenesis. It is produced by various cell types, including epithelial cells, and has been implicated in several chronic inflammatory diseases. Research indicates that elevated levels of CCL26 are associated with conditions such as asthma, rhinitis, and atopic dermatitis, highlighting its potential as a biomarker for these diseases. The study of CCL26 has garnered significant interest due to its role in mediating the Th2-type immune response and its involvement in tissue remodeling and fibrosis. Understanding the mechanisms of CCL26 action and signaling pathways could unveil new therapeutic targets for the treatment of allergic diseases and other related disorders. Given the importance of eosinophil infiltration in chronic inflammation, recombinant CCL26 protein studies aim to elucidate its functions in vivo and in vitro, providing insights into potential interventions. Furthermore, the potential use of CCL26 in developing novel therapeutic strategies or targeted treatments could advance the current paradigm of managing allergic diseases, underscoring the need for continued research in this area.